Adaptive pathways: EMA still leaves open questions unanswered

August 09, 2016

At the beginning of August, the European Medicines Agency (EMA) published a report on a pilot project of a new accelerated path for drug approval (adaptive pathways). In this approval procedure, for a highly restricted population drugs are to be launched on the market faster based on less evidence. Further data on effectiveness, safety, and benefit for broader use are only to be generated after drug approval within everyday health care - as so-called real world data.

The German Institute for Quality and Efficiency in Health Care (IQWiG) again sees its concerns about adaptive pathways confirmed by the EMA report. This is because evidently neither industry nor EMA has a concept as to how real world data can be used after drug approval to allow drawing reliable conclusions on benefit and harm.

Scientists and consumer advocates criticize concept

The concept has been criticized internationally for some time now: For instance, scientists not only question the assumptions underpinning the concept, but also point to difficulties with its implementation. The European Consumer Organization (BEUC) see risks for patients and criticizes the lack of transparency in the development and implementation of the concept. On several occasions, IQWiG too has critically discussed the adaptive pathways concept, most recently at its Autumn Symposium in November 2015.

Detailed information is lacking

EMA's final report on the pilot project, which started in 2014, was expected all the more urgently. However, the report now published fails to provide detailed information on the 7 test runs selected within the pilot project, the development programmes planned for these pilot cases, or the methods to be applied.

EMA justifies this information gap by referring to the confidential nature of the consultations and the trade and business secrets of the companies involved. However, in view of the importance of the pilot project for drug development and the potential consequences of the considerable changes in approval procedures for patients, concealment of the content and results of the discussions seems unacceptable.

Limitations of real world data become clear

But even without detailed information, the report allows conclusions on a key component of adaptive pathways, namely the use of real world data after drug approval. The limitations of such data, which became clear at the IQWiG Autumn Symposium, are confirmed by EMA's pilot project.

For instance, EMA draws an extremely sobering conclusion here, stating that "The majority of the plans were vague in terms of the purpose of collection of real world data to supplement RCTs, and on the practical elements for implementation there was insufficient detail in the submitted proposals to explore the refinement of the safety profile, and even less about to what extent efficacy could be confirmed or augmented in the post-authorisation phase. A critical discussion on the quality, potential for bias, and reliability of the data acquired in the post authorisation setting, and their suitability for regulatory and HTA purpose, was lacking."

EMA does not make its own proposals

If EMA views industry's proposals to be so meagre, one would expect that the Agency would make its own proposals as to how real world data could be used after drug approval - but one searches in vain for such proposals in their report. However, generating real world data after drug approval and using them in a way that allows robust conclusions on benefit and harm is a key component of the adaptive pathways concept. If this is still lacking, then it would be high time to pause for a moment and rethink the whole concept, instead of considering more drugs in the consultations on adaptive pathways, as planned by EMA.

Institute for Quality and Efficiency in Health Care

Related Health Care Articles from Brightsurf:

Study evaluates new World Health Organization Labor Care Guide for maternity care providers
The World Health Organization developed the new Labor Care Guide to support clinicians in providing good quality, women-centered care during labor and childbirth.

Six ways primary care "medical homes" are lowering health care spending
New analysis of 394 U.S. primary care practices identifies the aspects of care delivery that are associated with lower health care spending and lower utilization of emergency care and hospital admissions.

Modifiable health risks linked to more than $730 billion in US health care costs
Modifiable health risks, such as obesity, high blood pressure, and smoking, were linked to over $730 billion in health care spending in the US in 2016, according to a study published in The Lancet Public Health.

Spending on primary care vs. other US health care expenditures
National health care survey data were used to assess the amount of money spent on primary care relative to other areas of health care spending in the US from 2002 to 2016.

MU Health Care neurologist publishes guidance related to COVID-19 and stroke care
A University of Missouri Health Care neurologist has published more than 40 new recommendations for evaluating and treating stroke patients based on international research examining the link between stroke and novel coronavirus (COVID-19).

Large federal program aimed at providing better health care underfunds primary care
Despite a mandate to help patients make better-informed health care decisions, a ten-year research program established under the Affordable Care Act has funded a relatively small number of studies that examine primary care, the setting where the majority of patients in the US receive treatment.

International medical graduates care for Medicare patients with greater health care needs
A study by a Massachusetts General Hospital research team indicates that internal medicine physicians who are graduates of medical schools outside the US care for Medicare patients with more complex medical needs than those cared for by graduates of American medical schools.

The Lancet Global Health: Improved access to care not sufficient to improve health, as epidemic of poor quality care revealed
Of the 8.6 million deaths from conditions treatable by health care, poor-quality care is responsible for an estimated 5 million deaths per year -- more than deaths due to insufficient access to care (3.6 million) .

Under Affordable Care Act, Americans have had more preventive care for heart health
By reducing out-of-pocket costs for preventive treatment, the Affordable Care Act appears to have encouraged more people to have health screenings related to their cardiovascular health.

High-deductible health care plans curb both cost and usage, including preventive care
A team of researchers based at IUPUI has conducted the first systematic review of studies examining the relationship between high-deductible health care plans and the use of health care services.

Read More: Health Care News and Health Care Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to